Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award

Recognition reflects employee feedback and comes as UCB expands its Georgia footprint through a $2 billion investment in a new biomanufacturing campus expected to create more than 330 jobs. ATLANTA , Aug. 16, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company with its U.S. headquarters in metro Atlanta, has been named a winner of the 2026 Metro Atlanta Top Workplaces Award by Axios . As UCB expands its presence in Georgia, the Top Workplaces award reinforces the company's long-term investment in the state, its growing life sciences offering, and its overall culture that attracts, develops, and retains the talent needed to support innovation and a reliable medicine supply for U.S. patients. UCB has maintained its U.S. headquarters in metro Atlanta for more than 30 years and employs more than 400 people in Georgia. Earlier this year, UCB announced a $2 billion investment in a new biomanufacturing campus in Gwinnett County expected to create an additional 330+ permanent, highly-skilled jobs and generate an estimated $5 billion in economic impact. "This recognition is especially meaningful because it reflects the voices and experiences of our people," said Taco van Tiel, Head of UCB, U.S. "As UCB continues to invest in Georgia, including through our planned U.S. biologics manufacturing site, our ability to attract and support top talent will be central to delivering on our purpose for patients. We are proud to be part of the metro Atlanta community and to continue building a workplace where employees feel empowered to contribute, grow, and make an impact." EMPLOYEE FEEDBACK DRIVES TOP WORKPLACE RECOGNITION Awarded to fewer than 60 organizations with 159-499 employees across metro Atlanta, the recognition is based solely on employee feedback collected through a confidential third-party survey administered by Energage. UCB was previously a recipient of this award in 2021 . "Creating an environment where talented people can do their best work is fundamental to our success at UCB. This recognition reflects the culture our employees have helped build, one rooted in collaboration, growth, and a shared commitment to improving the lives of people living with severe diseases," said Michele Ehler, Head of U.S. Talent, UCB, "We always strive to create a workplace where employees feel valued and empowered to make a difference, and we remain focused on investing in them as we grow and advance our mission in the years ahead." UCB remains focused on creating an environment where employees can thrive, develop their careers, and contribute to meaningful work. By continuing to invest in its people and culture, UCB is building the foundation needed to support future growth and deliver its commitment to patients. UCB'S GROWING PRESENCE IN GEORGIA Georgia plays a central role in UCB's long-term growth strategy in the United States. In addition to serving as the home of the company's U.S. headquarters, the state will become home to UCB's first U.S. biomanufacturing campus. FOR FURTHER INFORMATION: U.S. Communications Erica Puntel T 404.938.5359 email [email protected] About UCB in the U.S. UCB has maintained a significant U.S. presence for decades, including its U.S. headquarters and eight offices across six communities in California, Georgia, Massachusetts, North Carolina, Washington, and Washington, D.C. With nearly 2,000 U.S. employees focused on research, development, and commercial operations across the country, UCB is adding a U.S. biomanufacturing campus in Georgia, which will create 330+ new, highly skilled jobs. UCB has increased its U.S. workforce by more than 70% since 2017, with over 25% of U.S. employees dedicated to R&D. Over the last decade, UCB has made significant investments in U.S. companies through acquisitions and partnerships and has achieved 15 FDA approvals, advancing innovation, supporting high-quality jobs, and delivering meaningful progress for patients. About UCB UCB, Brussels, Belgium ( www.ucb.com ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Forward looking statements This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial informat